569 related articles for article (PubMed ID: 27991919)
21. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X
Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579
[TBL] [Abstract][Full Text] [Related]
22. Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model.
Zhao W; Wei L; Tan D; Su G; Zheng Y; He C; Mao ZJ; Singleton TP; Yin B
PLoS One; 2014; 9(10):e109198. PubMed ID: 25314317
[TBL] [Abstract][Full Text] [Related]
23. Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
Jahns-Streubel G; Reuter C; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
Leukemia; 1995 Nov; 9(11):1857-63. PubMed ID: 7475275
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C.
Cheng C; Yuan F; Chen XP; Zhang W; Zhao XL; Jiang ZP; Zhou HH; Zhou G; Cao S
Biomed Pharmacother; 2021 Oct; 142():111652. PubMed ID: 34112534
[TBL] [Abstract][Full Text] [Related]
25. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
26. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
[TBL] [Abstract][Full Text] [Related]
27. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
[TBL] [Abstract][Full Text] [Related]
28. HOTAIRM1 knockdown enhances cytarabine-induced cytotoxicity by suppression of glycolysis through the Wnt/β-catenin/PFKP pathway in acute myeloid leukemia cells.
Chen L; Hu N; Wang C; Zhao H
Arch Biochem Biophys; 2020 Feb; 680():108244. PubMed ID: 31904363
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of mTORC1/P70S6K pathway by Metformin synergistically sensitizes Acute Myeloid Leukemia to Ara-C.
Yuan F; Cheng C; Xiao F; Liu H; Cao S; Zhou G
Life Sci; 2020 Feb; 243():117276. PubMed ID: 31926250
[TBL] [Abstract][Full Text] [Related]
30. A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia.
Alloush HM; Anderson E; Martin AD; Ruddock MW; Angell JE; Hill PJ; Mehta P; Smith MA; Smith JG; Salisbury VC
Clin Chem; 2010 Dec; 56(12):1862-70. PubMed ID: 20921267
[TBL] [Abstract][Full Text] [Related]
31. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.
Taub JW; Huang X; Matherly LH; Stout ML; Buck SA; Massey GV; Becton DL; Chang MN; Weinstein HJ; Ravindranath Y
Blood; 1999 Aug; 94(4):1393-400. PubMed ID: 10438727
[TBL] [Abstract][Full Text] [Related]
32. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
[TBL] [Abstract][Full Text] [Related]
33. The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement.
Castagnola C; Nozza A; Corso A; Bernasconi C
Haematologica; 1997; 82(5):577-80. PubMed ID: 9407724
[TBL] [Abstract][Full Text] [Related]
34. Rapid in-vitro testing for chemotherapy sensitivity in leukaemia patients.
Anderson E; Salisbury V
Adv Biochem Eng Biotechnol; 2014; 145():189-214. PubMed ID: 25216956
[TBL] [Abstract][Full Text] [Related]
35. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
36. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
Yamauchi T; Kawai Y; Goto N; Kishi S; Imamura S; Yoshida A; Urasaki Y; Fukushima T; Iwasaki H; Tsutani H; Masada M; Ueda T
Jpn J Cancer Res; 2001 Sep; 92(9):975-82. PubMed ID: 11572766
[TBL] [Abstract][Full Text] [Related]
37. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
Morsy MHA; Lilienthal I; Lord M; Merrien M; Wasik AM; Sureda-Gómez M; Amador V; Johansson HJ; Lehtiö J; Garcia-Torre B; Martin-Subero JI; Tsesmetzis N; Tao S; Schinazi RF; Kim B; Sorteberg AL; Wickström M; Sheppard D; Rassidakis GZ; Taylor IA; Christensson B; Campo E; Herold N; Sander B
Blood; 2024 Jan; 143(19):1953-1964. PubMed ID: 38774451
[TBL] [Abstract][Full Text] [Related]
38. Sugar-modified poly(propylene imine) dendrimers as drug delivery agents for cytarabine to overcome drug resistance.
Szulc A; Pulaski L; Appelhans D; Voit B; Klajnert-Maculewicz B
Int J Pharm; 2016 Nov; 513(1-2):572-583. PubMed ID: 27667754
[TBL] [Abstract][Full Text] [Related]
39. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
[TBL] [Abstract][Full Text] [Related]
40. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]